Reaction Details Report a problem with these data
Target
IgG receptor FcRn large subunit p51
Ligand
BDBM50270982
Substrate
n/a
Meas. Tech.
ChEMBL_552584 (CHEMBL956456)
IC50
33000±n/a nM
Citation
 Mezo, AR; McDonnell, KA; Castro, A; Fraley, C Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem 16:6394-405 (2008) [PubMed]  Article 
Target
Name:
IgG receptor FcRn large subunit p51
Synonyms:
FCGRN_HUMAN | FCGRT | FCRN
Type:
PROTEIN
Mol. Mass.:
39742.86
Organism:
Homo sapiens (Human)
Description:
ChEMBL_627631
Residue:
365
Sequence:
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
  
Inhibitor
Name:
BDBM50270982
Synonyms:
(2S)-1-{2-[(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]hexanamido]-3-hydroxybutanamido]acetamido}-3-(1H-imidazol-5-yl)propanamido]-3-phenylpropanamido]acetamido}acetamido)-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-4-carboxybutanamido]-3-carbamoylpropanamido]acetyl}pyrrolidine-2-carboxylic acid | CHEMBL510066
Type:
Small organic molecule
Emp. Form.:
C87H125N25O24
Mol. Mass.:
1905.0765
SMILES:
CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:4.4,83.87,27.35,54.64,117.121,76.79,41.43,wD:132.138,104.109,89.91,16.24,65.75,45.52,108.112,(31.59,-13.45,;31.59,-14.99,;32.92,-15.76,;30.26,-15.75,;30.26,-17.31,;29.04,-18.2,;27.69,-17.48,;27.69,-15.93,;26.41,-18.35,;25.19,-17.45,;23.82,-18.19,;23.83,-19.73,;22.55,-17.32,;21.33,-18.21,;19.96,-17.49,;19.97,-15.95,;18.69,-18.35,;18.69,-19.91,;20.02,-20.69,;21.36,-19.91,;22.7,-20.69,;22.7,-22.23,;21.36,-23,;20.02,-22.23,;17.47,-17.47,;16.11,-18.19,;16.12,-19.73,;14.84,-17.33,;14.84,-15.79,;16.17,-15.02,;17.63,-15.5,;18.55,-14.28,;17.65,-13.02,;16.19,-13.48,;13.46,-18.22,;12.1,-17.49,;12.11,-15.95,;10.82,-18.35,;9.62,-17.47,;8.26,-18.19,;8.27,-19.73,;6.98,-17.33,;5.78,-18.22,;4.48,-17.4,;4.53,-15.87,;3.12,-18.12,;3.06,-19.65,;4.35,-20.46,;4.3,-21.98,;5.58,-22.78,;5.53,-24.3,;1.82,-17.31,;.46,-18.03,;.47,-19.58,;-.82,-17.17,;-.82,-15.62,;.51,-14.84,;1.85,-15.61,;3.18,-14.84,;3.18,-13.29,;1.85,-12.53,;.51,-13.29,;-2.04,-18.05,;-3.39,-17.33,;-3.38,-15.78,;-4.67,-18.2,;-4.67,-19.75,;-3.33,-20.52,;-3.33,-22.06,;-2.01,-22.79,;-1.97,-24.33,;-.61,-25.06,;-3.28,-25.13,;-5.9,-17.31,;-7.26,-18.03,;-7.25,-19.58,;-8.53,-17.17,;-9.75,-18.05,;-8.53,-15.62,;-7.2,-14.84,;-7.2,-13.3,;-8.53,-12.53,;-5.87,-12.53,;6.99,-15.79,;5.66,-15.02,;8.32,-15.02,;31.54,-18.18,;31.54,-19.73,;32.89,-17.45,;34.11,-18.33,;34.11,-19.88,;33.29,-21.2,;34.03,-22.55,;33.22,-23.87,;31.68,-23.82,;30.88,-25.14,;30.95,-22.47,;31.75,-21.16,;35.39,-17.47,;35.39,-15.92,;36.74,-18.19,;36.97,-19.71,;38.49,-19.98,;39.34,-18.49,;38.14,-17.51,;38.41,-16,;37.23,-15.02,;39.85,-15.47,;41.02,-16.46,;40.76,-17.97,;41.93,-18.94,;41.67,-20.44,;40.25,-20.96,;42.84,-21.41,;42.46,-15.93,;42.72,-14.42,;43.65,-16.91,;44.77,-16.1,;44.77,-14.66,;46.01,-13.95,;47.23,-14.67,;46.01,-12.53,;45.96,-16.89,;45.96,-18.32,;47.2,-16.22,;48.33,-17.05,;49.51,-16.24,;49.52,-14.82,;50.77,-16.91,;50.97,-18.33,;52.38,-18.58,;53.05,-17.32,;52.06,-16.29,;52.31,-14.89,;53.65,-14.4,;51.22,-13.96,)|
Structure:
Search PDB for entries with ligand similarity: